Plasma exchange using dextran 40-electrolyte solution as the sole replacement fluid in malignant paraproteinemia

Area of Science:

• Nephrology
• Hematology
• Clinical Pharmacology

Background:

• Plasma exchange is a critical therapy for various hematologic and oncologic conditions.
• Malignant paraproteinemias, such as Waldenström's macroglobulinemia and multiple myeloma, often require intensive plasma exchange.
• The choice of replacement fluid impacts patient safety and therapeutic efficacy.

Purpose of the Study:

• To evaluate the safety and efficacy of using 3 percent Dextran 40-electrolyte solution as the sole replacement fluid during plasma exchange.
• To assess the impact of this fluid on plasma colloid osmotic pressure and hemostatic function.
• To determine the clinical tolerance and complication rate associated with this therapeutic approach.

Main Methods:

• Plasma exchange was performed using an automated blood cell separator in 11 patients with malignant paraproteinemia.
• A total of 3.2 L of plasma was exchanged, with replacement by an equal volume of 3 percent Dextran 40-electrolyte solution.
• No protein-containing solutions were administered during or after the procedures.

Main Results:

• Despite significant post-exchange hypoalbuminemia, plasma colloid osmotic pressure remained relatively stable due to the dextran infusion.
• Hemostatic abnormalities observed were comparable to those seen with albumin replacement.
• The procedure was well-tolerated clinically, with no serious complications reported.

Conclusions:

• 3 percent Dextran 40-electrolyte solution can be safely employed as the exclusive replacement fluid in intensive plasma exchange programs.
• This fluid is a viable alternative for patients with malignant paraproteinemia, offering stable osmotic pressure and acceptable hemostatic profiles.
• The findings support the use of dextran-based solutions in specific therapeutic contexts, potentially reducing reliance on protein-based products.